Our firm represented the venture arm of a Fortune 50 pharmaceutical company in a $17 million convertible preferred stock investment in a healthcare IT company.
Fortune 50 Pharmaceutical Company Preferred Stock Offering
Lead Contacts
Our firm represented the venture arm of a Fortune 50 pharmaceutical company in a $17 million convertible preferred stock investment in a healthcare IT company.